MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Apellis Pharmaceuticals Inc

Fermé

SecteurSoins de santé

19.46 -3.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

19.19

Max

19.73

Chiffres clés

By Trading Economics

Revenu

-56M

-92M

Ventes

-46M

167M

Marge bénéficiaire

-55.292

Employés

705

EBITDA

-56M

-80M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+85.88% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-54M

2.5B

Ouverture précédente

22.55

Clôture précédente

19.46

Sentiment de l'Actualité

By Acuity

71%

29%

339 / 376 Classement par Healthcare

Apellis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 juil. 2025, 21:01 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 20:46 UTC

Résultats

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 juil. 2025, 20:39 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 20:36 UTC

Résultats

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 juil. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 juil. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 juil. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 juil. 2025, 18:24 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 juil. 2025, 18:19 UTC

Résultats

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 juil. 2025, 18:11 UTC

Acquisitions, Fusions, Rachats

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 juil. 2025, 18:11 UTC

Résultats

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 juil. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 juil. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 juil. 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 16:04 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 juil. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 juil. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 juil. 2025, 15:47 UTC

Market Talk
Résultats

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparaison

Variation de prix

Apellis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

85.88% hausse

Prévisions sur 12 Mois

Moyen 37.25 USD  85.88%

Haut 60 USD

Bas 17 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

10

Achat

7

Maintien

0

Vente

Sentiment

By Acuity

339 / 376Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.